Dr. Lindsey Michelle Charo, MD

Dr. Charo practices at Kaiser Permanente Zion Medical Center in San Diego, California, part of Kaiser Permanente.

Dr. Charo's NPI, 1316202849, was assigned on July 11, 2012. Dr. Charo graduated from UC San Diego School of Medicine in 2012. Dr. Charo holds California license A127097.

Dr. Charo's primary practice is Kaiser Permanente Zion Medical Center, at 4647 Zion Ave, San Diego, CA 92120 in San Diego County. The practice phone is (619) 528-5000.

Dr. Charo's primary practice is Kaiser Permanente Zion Medical Center in San Diego, California, part of Kaiser Permanente. The medical group on file is Southern California Permanente Medical Group. Dmand AI also links Dr. Charo to 2 more medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Charo practices, 2 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Charo's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Charo is board certified in gynecologic oncology by the American Board of Obstetrics and Gynecology. Dr. Charo is licensed in California.

Dmand AI lists hysterectomy, menopause and ovarian cyst among the conditions Dr. Charo treats.

CMS data shows 1,311 Medicare services from Dr. Charo across 14 procedure codes in 2024, for 101 Medicare patients. Medicare paid $22,727 for them. Every service was in an office.

CMS counts 101 Medicare patients who saw Dr. Charo in 2024. The largest group is 65 to 74, with 50 patients. 75% of them have high cholesterol, and 69% have high blood pressure. 14% are also on Medicaid. Their average risk score is 1.84, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Charo's median patient age at 66, with 100% women.

In 2024, Dr. Charo wrote 109 Medicare Part D claims for 66 patients. 93% of them were for generic drugs. CMS names the drug for 36 of them, across 2 drugs with 11 or more claims each, at $643 in total drug cost. In 2023, CMS named 16 claims across 1 drug.

Dmand AI links 16 papers to Dr. Charo, published from 2011 to 2021. 2020 was the busiest year, with 4. The most frequent topics are Genital Neoplasms, Female, Ovarian Neoplasms and Cytoreduction Surgical Procedures. Dr. Charo has published most often in Gynecol Oncol. Dr. Charo's most frequent co-authors are Ramez Nassef Eskander, MD, Michael Thomas McHale, MD and Pratibha Sareen Binder, MD.

CMS Open Payments shows 87 general payments to Dr. Charo from 13 drug and device companies from 2019 to 2024. Food and beverage make up the largest share, 98% of the total. Merck Sharp & Dohme Corporation paid the most, $592.

Dr. Charo graduated from UC San Diego School of Medicine in 2012.

Dr. Charo is in network with 2 carriers, including Blue Cross Blue Shield of Michigan and Kaiser Permanente. HMO plans come from the most carriers, 2. Check the plan with the practice before a visit.